Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.

Ainhoa Madariaga,Swati Garg,Nairi Tchrakian,Neesha C. Dhani,Waldo Jimenez,Stephen Welch,Helen Mackay,Josee-Lyne Ethier,Lucy Gilbert,Angela Rodriguez,Lucy Chan,Valerie Bowering,Blaise A. Clarke,Tracy Stockley,Xuan Li,Lisa Wang,Smitha Udagani,Amit M. Oza,Stephanie Lheureux

Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.

2021

Ainhoa Madariaga
Swati Garg
Nairi Tchrakian
Neesha C. Dhani
Waldo Jimenez
Stephen Welch
Helen Mackay
Josee-Lyne Ethier
Lucy Gilbert
Angela Rodriguez
Lucy Chan
Valerie Bowering
Blaise A. Clarke
Tracy Stockley
Xuan Li
Lisa Wang
Smitha Udagani
Amit M. Oza
Stephanie Lheureux

5574Background: Treatment options in recurrent endometrial carcinoma (EC) are limited. Endometrioid EC shows alterations in PTEN, a possible biomarker of response to PARP inhibitors (PARPi). Simila...

Keywords:

treatment options
Carcinoma
Medicine
Biomarker (medicine)
Cancer research
PTEN
anti pd 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations